We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS PULLS PLUG ON SERZONE, GENERIC IMPACT UNCERTAIN
BMS PULLS PLUG ON SERZONE, GENERIC IMPACT UNCERTAIN
June 1, 2004
Bristol-Myers Squibb’s (BMS’) recent decision to stop marketing its antidepressant Serzone (nefazodone HCl) will give generics 100 percent of the market of the former top-selling product — a situation that presents mixed opportunities for generic firms, according to industry observers.